据法新社1月28日报道，东京大学官方于28日公开道歉。此前该校出现了第二起医学教授因在东大工作期 间受贿被捕的事件。 百万用户都在看 利好突袭！马斯克，重大宣布！欧盟也有大动作！事关商业航天 直线拉升！光刻机巨头，传来重磅利好！AI，再度引爆！ 突发！超2900架次航班，紧急取消！这一品种狂飙70%！特大风暴，突袭美国 跨界并购！牛股尾盘，封死涨停！A股又一信号闪现 尾盘异动！A股，三大信号"闪现" 上周，东京警方逮捕了该校皮肤病学教授佐藤伸一，他涉嫌接受昂贵的餐点、光顾女招待俱乐部，甚至接 受性服务。 东京大学校长藤井辉夫在新闻发布会上表示："作为一所教育和研究机构，我们严重辜负了社会的信任， 我们致以最深切、最诚挚的歉意。"他承诺将对学校进行改革。 报道称，去年11月，该校的一名整形外科医生被捕，据称其接受了一家医疗设备制造商的贿赂。 佐藤涉嫌接受总部位于东京的日本化妆品协会的各种好处，该集团正在探寻将大麻二酚（CBD）用于护肤 品的商业机会。 据《朝日新闻》报道，日本化妆品协会希望开展一项关于CBD的联合研究，欲利用东大的声望展示该产品 在改善肤质方面的效用。 藤井辉夫还承认，东京检方正在调查一名曾与佐 ...

据法新社1月28日报道，东京大学官方于28日公开道歉。此前该校出现了第二起医学教授因在东大工作 期间受贿被捕的事件。 来源：参考消息 编辑：朱嘉琪 上周，东京警方逮捕了该校皮肤病学教授佐藤伸一，他涉嫌接受昂贵的餐点、光顾女招待俱乐部，甚至 接受性服务。 校对：张丽媛 东京大学校长藤井辉夫在新闻发布会上表示："作为一所教育和研究机构，我们严重辜负了社会的信 任，我们致以最深切、最诚挚的歉意。"他承诺将对学校进行改革。 审核：张晓雅 报道称，去年11月，该校的一名整形外科医生被捕，据称其接受了一家医疗设备制造商的贿赂。佐藤涉 嫌接受总部位于东京的日本化妆品协会的各种好处，该集团正在探寻将大麻二酚（CBD）用于护肤品 的商业机会。 据《朝日新闻》报道，日本化妆品协会希望开展一项关于CBD的联合研究，欲利用东大的声望展示该 产品在改善肤质方面的效用。 藤井辉夫还承认，东京检方正在调查一名曾与佐藤共事但已离职的前皮肤病学副教授在贿赂丑闻中的角 色。 ...

Core Viewpoint - The restructuring plan of Rhein Biotech (002166.SZ) involves a significant change in control, with the original controlling shareholder, Qin Benjun, transferring 8.09% of shares and relinquishing 25.5% of voting rights to introduce a new main shareholder, Guangzhou Defu Nutrition, while also acquiring 80% of Beijing Jinkangpu's equity to extend its business into the nutritional supplement sector [2][3][4]. Group 1: Shareholder Changes - Qin Benjun will transfer shares at a price of 10.76 CNY per share, totaling 645.6 million CNY, which is a premium of over 20% compared to the last closing price before suspension [2][4]. - Following the resumption of trading, Rhein Biotech's stock hit a daily limit up, reaching 9.57 CNY per share, marking a new high for the year and a market capitalization of 7.097 billion CNY [3]. - Qin Benjun's exit is attributed to financial pressures and operational difficulties faced by the company, including a recent penalty from the China Securities Regulatory Commission for market manipulation [5][6]. Group 2: Financial Performance and Challenges - Rhein Biotech's net profit from 2021 to 2024 showed significant volatility, with figures of 118 million CNY, 179 million CNY, 83 million CNY, and 163 million CNY, reflecting a concerning stability in profitability [7]. - In the first three quarters of 2025, the company reported revenue of 1.272 billion CNY, an increase of 8.73% year-on-year, but net profit decreased by 30.73% to 70.395 million CNY, indicating a tightening cash flow situation [9]. - As of September 2025, the company had only 255 million CNY in cash but faced short-term interest-bearing liabilities of 807 million CNY, highlighting liquidity issues [9]. Group 3: Strategic Acquisitions - The acquisition of 80% of Beijing Jinkangpu is part of a strategy to create a closed-loop supply chain from raw materials to formulation solutions in the nutritional supplement field [2][10]. - Beijing Jinkangpu reported a revenue of 432 million CNY and a net profit of 70.2658 million CNY in 2024, with a relatively stable financial condition, making it a strategic fit for Rhein Biotech [12]. - The acquisition is expected to enhance Rhein Biotech's product offerings in the dairy sector and leverage its global sales network for international expansion [15]. Group 4: Market Context and Future Prospects - The recent decision by the Ministry of Commerce to impose temporary anti-subsidy duties on EU dairy products may benefit domestic dairy producers, potentially creating a favorable environment for Rhein Biotech's new business direction [14]. - The U.S. federal government's recent reforms on cannabis regulation may open new opportunities for Rhein Biotech's industrial hemp business, particularly in CBD extraction [15][16]. - The establishment of Guangzhou Defu Nutrition, which is closely linked to the new controlling shareholders, indicates a strategic move to consolidate assets and enhance operational efficiency within the healthcare investment sector [13].

Core Viewpoint - The company is transitioning from its initial phase of basic chemical production to a more advanced stage focused on optimizing core industries and enhancing specialized industrial chains through its "One Body, Two Wings" strategy [2][3][6]. Group 1: Project Developments - The new integrated propylene value chain project was completed in just over eight months, marking it as a significant project in Nanjing Jiangbei New Area with an investment of over 1 billion yuan [2][5]. - The project utilizes advanced international technology, producing propylene from self-sourced materials and combining it with syngas and hydrogen to manufacture octanol [5][6]. - The project achieved successful trial production and sold 80 tons of octanol on the same day, demonstrating rapid recovery of investment [5][6]. Group 2: Financial Performance - In 2021, the company's net profit reached 1.008 billion yuan, a 184.01% increase year-on-year, but fell sharply to 52.9 million yuan in 2022 due to geopolitical issues affecting coal supply and prices [3][4]. - The company aims to maintain positive cash flow and inject new growth into its operations through early revenue-generating projects like the octanol production [7][12]. Group 3: Strategic Direction - The "One Body, Two Wings" strategy encompasses clean energy and high-end chemical materials, with a focus on technological innovation and extending the industrial chain [8][9]. - The company is exploring new markets in high-performance materials, including ultra-high molecular weight polyethylene (UHMWPE) and polyolefin elastomers (POE) [7][8]. - Collaboration with academic institutions aims to enhance capabilities in synthetic biology, targeting new product development and market expansion [10][11]. Group 4: Operational Enhancements - The company is restructuring its management and talent strategy to support its upgraded operational capabilities, ensuring efficient project execution and production optimization [11][12]. - Emphasis is placed on flexible production techniques and digital management to adapt to market fluctuations and improve operational efficiency [12].